London, United Kingdom — Plexus Ventures is pleased to announce the successful completion of a divestment project. Plexus provided transaction services to AstraZeneca UK Limited in the divesture of three of the company’s antimalarial brands — PaludrineTM, AvloclorTM and SavarineTM — to Alliance Pharmaceuticals Limited. The products are sold mainly in the UK and France.
Michael O’Sullivan, Managing Director of Plexus Ventures UK office, commented: We are pleased to have successfully completed our first transaction for AstraZeneca. Our strong performance on behalf of our multinational clients like AstraZeneca has led to an ever increasing number of divestment assignments for Plexus Ventures. We thank AstraZeneca for their confidence in us.